Nitric oxide - Revision history

Tony.Wang at 03:05, 31 August 2021

2021-08-31T03:05:41Z

← Older revision		Revision as of 20:05, 30 August 2021
Line 3:		Line 3:
	\| drug_class =		\| drug_class =
	\| drug_class_color =		\| drug_class_color =
	\| uses =		\| uses = Pulmonary HTN; RHF
	\| contraindications =		\| contraindications = severe LHF; R to L shunt
	\| routes =		\| routes = Inhalational
	\| dosage =		\| dosage = 1-20 ppm (parts per million)
			\| mechanism =
			\| adverse_effects =
			\| time_onset =
			\| duration =
			\| metabolism =
			\| halflife_redistribution =
			\| halflife_elimination =
			\| clearance =
			\| protein_binding =
	}}		}}

Line 14:		Line 23:

	* Pulmonary HTN		* Pulmonary HTN
	** After heart transplant
	* Right ventricular failure		* Right ventricular failure

Line 20:		Line 28:

	=== Absolute contraindications<!-- List absolute contraindications for use of the drug. If none, this section may be removed. --> ===		=== Absolute contraindications<!-- List absolute contraindications for use of the drug. If none, this section may be removed. --> ===

			* Severe left heart dysfunction
			* Congenital heart conditions with dependent right to left shunt (e.g. interrupted aortic arch, critical aortic stenosis, hypoplastic left heart syndrome), which would shunt blood away from systemic circulation toward pulmonary circulation

	=== Precautions<!-- List precautions for use of the drug. If none, this section may be removed. --> ===		=== Precautions<!-- List precautions for use of the drug. If none, this section may be removed. --> ===

Tony.Wang at 02:33, 31 August 2021

2021-08-31T02:33:32Z

← Older revision		Revision as of 19:33, 30 August 2021
Line 9:		Line 9:
	}}		}}

	Nitric oxide is a naturally occurring endothelial-derived vasodilator that exhibits most of its vasodilatory effects in the pulmonary vasculature.<ref>{{Cite journal\|last=Ichinose\|first=Fumito\|last2=Roberts\|first2=Jesse D.\|last3=Zapol\|first3=Warren M.\|date=2004-06-29\|title=Inhaled Nitric Oxide\|url=https://www.ahajournals.org/doi/10.1161/01.cir.0000134595.80170.62\|journal=Circulation\|volume=109\|issue=25\|pages=3106–3111\|doi=10.1161/01.CIR.0000134595.80170.62}}</ref> It is frequently indicated for patients with right heart failure and hypoxemia. It exists as a colorless odorless gas, and is administered inhalationally.		Nitric oxide (NO) is a naturally occurring endothelial-derived vasodilator that exhibits most of its vasodilatory effects in the pulmonary vasculature.<ref>{{Cite journal\|last=Ichinose\|first=Fumito\|last2=Roberts\|first2=Jesse D.\|last3=Zapol\|first3=Warren M.\|date=2004-06-29\|title=Inhaled Nitric Oxide\|url=https://www.ahajournals.org/doi/10.1161/01.cir.0000134595.80170.62\|journal=Circulation\|volume=109\|issue=25\|pages=3106–3111\|doi=10.1161/01.CIR.0000134595.80170.62}}</ref> It is frequently indicated for patients with right heart failure and hypoxemia. It exists as a colorless odorless gas, and is administered inhalationally.

	== Uses<!-- Describe uses of the drug. If appropriate, add subsections for each indication. --> ==		== Uses<!-- Describe uses of the drug. If appropriate, add subsections for each indication. --> ==

			* Pulmonary HTN
			** After heart transplant
			* Right ventricular failure

	== Contraindications<!-- List contraindications and precautions for use of the drug. --> ==		== Contraindications<!-- List contraindications and precautions for use of the drug. --> ==
Line 24:		Line 28:

	==== Mechanism of action<!-- Describe the mechanism of action for the primary uses of the drug. --> ====		==== Mechanism of action<!-- Describe the mechanism of action for the primary uses of the drug. --> ====
			Nitric oxide diffuses to smooth muscle of pulmonary vasculature -> activates soluble guanylate cyclase (sGC) -> converts GTP to cGMP -> activates protein kinase G -> increases Ca2+ reuptake -> decreased calcium decreasing myosin phosphorylation -> relaxation of smooth muscle.

	==== Adverse effects<!-- Describe any potential adverse effects of the drug. --> ====		==== Adverse effects<!-- Describe any potential adverse effects of the drug. --> ====
Line 32:		Line 37:

	== History<!-- Describe the historical development of the drug. --> ==		== History<!-- Describe the historical development of the drug. --> ==
			Initially discovered in 1987. Won Nobel Prize in Physiology and Medicine in 1998.

	== References ==		== References ==

	[[Category:Drug reference]]		[[Category:Drug reference]]

Tony.Wang: Page creation

2021-08-30T17:53:40Z

Page creation

New page

{{Infobox drug reference
| trade_names =
| drug_class =
| drug_class_color =
| uses =
| contraindications =
| routes =
| dosage =
}}

Nitric oxide is a naturally occurring endothelial-derived vasodilator that exhibits most of its vasodilatory effects in the pulmonary vasculature.<ref>{{Cite journal|last=Ichinose|first=Fumito|last2=Roberts|first2=Jesse D.|last3=Zapol|first3=Warren M.|date=2004-06-29|title=Inhaled Nitric Oxide|url=https://www.ahajournals.org/doi/10.1161/01.cir.0000134595.80170.62|journal=Circulation|volume=109|issue=25|pages=3106–3111|doi=10.1161/01.CIR.0000134595.80170.62}}</ref> It is frequently indicated for patients with right heart failure and hypoxemia. It exists as a colorless odorless gas, and is administered inhalationally.

== Uses ==

== Contraindications ==

=== Absolute contraindications ===

=== Precautions ===

== Pharmacology ==

=== Pharmacodynamics ===

==== Mechanism of action ====

==== Adverse effects ====

=== Pharmacokinetics ===

== Chemistry and formulation ==

== History ==

== References ==

[[Category:Drug reference]]